Emergent BioSolutions stock gains 7.11 percent on October 5

Published on 10/05/2026 at 17:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Emergent BioSolutions stock was trading at USD 6.78 on October 5, 2026, while second-quarter revenue reached USD 234.30 million. Six analysts rate it Hold with a USD 10.00 average target.

EBS, US29089Q1058, Illustration mit AI erstellt.

Emergent BioSolutions (ISIN US29089Q1058) was trading at USD 6.78 on the NYSE on October 5, 2026, up 7.11 percent from the previous close. The move puts the biopharmaceutical company 51.8 percent below its 52-week high of USD 14.06, while its market capitalization stood at USD 349.8 million.

Quarterly revenue beats estimates

Emergent reported second-quarter 2026 revenue of USD 234.30 million and earnings per share of USD 0.60, according to MarketBeat. Revenue exceeded the USD 177.50 million consensus by USD 56.80 million, while EPS came in USD 0.68 above the expected USD -0.08.

The finance figures show a sharp quarter-to-quarter change: revenue rose from USD 156.10 million in the first quarter to USD 234.30 million in the second quarter, while diluted EPS moved from USD 0.07 to USD 0.60. The comparison points to stronger operating performance in the latest reported quarter, although the company remains exposed to uneven product demand.

Debt reduction supports the turnaround

At the H.C. Wainwright conference on September 14, 2026, management said first-half revenue reached USD 390 million, up USD 27 million from the prior-year period, while adjusted EBITDA increased to USD 132 million from USD 112 million. Investing.com reported that gross debt had fallen to USD 515 million after refinancing and bond repurchases.

The balance-sheet focus matters because management also described the medical countermeasures business as the main growth engine, with second-quarter revenue of USD 168 million. NARCAN remains commercially important, but management cited pricing pressure from four generic competitors and a market share of 50 percent.

Analysts see room above the price

MarketBeat reported a Hold consensus from six analysts, comprising three Buy ratings, one Hold rating and two Sell ratings. The average 12-month price target is USD 10.00, which lies 47.5 percent above the USD 6.78 price.

HC Wainwright reaffirmed a Buy rating and a USD 10.00 price target on September 9, 2026, while JPMorgan initiated coverage with an Underweight rating, according to MarketBeat. The split in ratings reflects the contrast between improved first-half operating figures and continued pricing and leverage risks.

Stock gains during October 5 trading

Emergent BioSolutions stock was last at USD 6.78 on the NYSE at 11:40 a.m. ET on October 5, 2026, with volume of 539,392 shares. The session range was USD 6.46 to USD 6.88, and the 52-week range was USD 4.36 to USD 14.06.